Phillygenin, a MELK Inhibitor, Inhibits Cell Survival and Epithelial–Mesenchymal Transition in Pancreatic Cancer Cells
Authors:
Open Access
- 1 April 2020
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 2833-2842
Abstract
Introduction: Pancreatic cancer (PC) is one of the leading causes of cancer, with the lowest 5-year survival rate of all cancer types. Given the fast metastasis of PC and its resistance to surgery, radiotherapy, chemotherapy, and combinations thereof, it is imperative to develop more effective anti-PC drugs. Phillygenin (PHI) has been reported to exert anti-cancer, anti-bacterial, and anti‐inflammatory properties. However, the mechanism of PHI in the development of PC is still unclear. Methods: The cytotoxicity of PHI in pancreatic cancer cells was evaluated by MTT assay, and clonogenic assay was used to test the anti-proliferation of PHI. The pro-apoptotic effect of PHI was detected by flow cytometry analysis. The changes of epithelial–mesenchymal transition (EMT) in pancreatic cancer cells treated with PHI were determined by Western blot. Transwell assay was used to test the migration and invasion of PC cells after treatment with PHI. Molecular docking was used to predict the potential binding site of candidate target with PHI. Results: PHI could inhibit the proliferation, migration, and EMT of PC cells (PANC-1 and SW1990) and induce its apoptosis. Analysis of the Cancer Genome Atlas database indicated that elevated MELK levels correlated with poor overall survival (OS) and disease-free survival (DFS) of PC patients. In addition, molecular modeling showed that PHI may potentially target the catalytic domain of maternal embryonic leucine zipper kinase (MELK). Overexpression of MELK muted the anti-PC effects of PHI. Conclusion: PHI holds promise as a potent candidate drug for the treatment of PC via targeted MELK.Keywords
This publication has 34 references indexed in Scilit:
- Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancerOncotarget, 2016
- ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SBJournal of Chemical Theory and Computation, 2015
- MELK—a conserved kinase: functions, signaling, cancer, and controversyClinical and Translational Medicine, 2015
- The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinitiesExpert Opinion on Drug Discovery, 2015
- Maternal embryonic leucine zipper kinase regulates pancreatic ductal, but not β -cell, regenerationPhysiological Reports, 2014
- Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamicsBioorganic & Medicinal Chemistry Letters, 2013
- PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory DataJournal of Chemical Theory and Computation, 2013
- UCSF Chimera, MODELLER, and IMP: An integrated modeling systemJournal of Structural Biology, 2012
- Interaction between phillygenin and human serum albumin based on spectroscopic and molecular dockingSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2012
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004